Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Metrics to compare | ORY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORYPeersSector | |
---|---|---|---|---|
P/E Ratio | −61.8x | −4.2x | −0.5x | |
PEG Ratio | 18.07 | 0.00 | 0.00 | |
Price/Book | 2.6x | 1.0x | 2.6x | |
Price / LTM Sales | 30.8x | 11.5x | 3.0x | |
Upside (Analyst Target) | 29.7% | 7,047.7% | 53.8% | |
Fair Value Upside | Unlock | 25.3% | 9.6% | Unlock |